YS-49 is an inhibitor of platelet aggregation.1 It inhibits ADP-, collagen-, or epinephrine-induced platelet aggregation in isolated human platelets (IC50s = 730, 92, and 3.4 ?M, respectively). YS-49 also inhibits platelet aggregation and production of thromboxane A2 (TXA2) induced by arachidonic acid in isolated rat platelets (IC50s = 3.3 and 32.8 ?M, respectively).2 It reduces LPS-induced contractions in isolated endothelium-denuded rat aortic strips in a concentration-dependent manner.3 YS-49 (50 mg/kg) decreases thrombus weight in a rat model of arterio-venous shunt thrombosis.1 It increases survival in a mouse model of septicemia induced by LPS when administered at doses of 10 and 20 mg/kg.3
1.Yun-Choi, H.S., Pyo, M.K., Park, K.M., et al.Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamineThromb. Res.104(4)249-255(2001) 2.Pyo, M.K., Kim, J.M., Jin, J.-L., et al.Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregationThromb. Res.120(1)81-86(2007) 3.Kang, Y.J., Koo, E.B., Lee, Y.S., et al.Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophagesBr. J. Pharmacol.128(2)357-364(1999)